Health & Environmental Research Online (HERO)


Print Feedback Export to File
8392994 
Journal Article 
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer 
Bitting, RL; Armstrong, AJ 
2013 
Yes 
Endocrine-Related Cancer
ISSN: 1351-0088
EISSN: 1479-6821 
20 
3 
R83-R99 
English 
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals and the high prevalence of activating PI3K/Akt/mTOR pathway alterations in prostate cancer, inhibitors of this pathway have great potential for clinical benefit. Here, we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer. Copyright © 2013 Society for Endocrinology. 
Akt; Androgen receptor signaling; Castration-resistant prostate cancer (CRPC); Combination therapy; MTOR; PI3K inhibitors; PI3K pathway